{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:26:56Z","timestamp":1791862016495,"version":"4.3.4"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EMIDDT"],"published-print":{"date-parts":[[2018,10,5]]},"DOI":"10.2174\/1871530318666180328111302","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T07:59:49Z","timestamp":1522310389000},"page":"547-554","source":"Crossref","is-referenced-by-count":50,"title":["Non-Alcoholic Fatty Pancreas Disease (NAFPD): A Silent Spectator or the Fifth Component of Metabolic Syndrome? A Literature Review"],"prefix":"10.2174","volume":"18","author":[{"given":"Bhupinder S.","family":"Romana","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harleen","family":"Chela","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine University of Missouri, Columbia, MO, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis E.","family":"Dailey","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatiha","family":"Nassir","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veysel","family":"Tahan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Endocrine, Metabolic & Immune Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/160803","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T10:57:32Z","timestamp":1538737052000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/160803\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,5]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,10,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871530318666180328111302","relation":{},"ISSN":["1871-5303"],"issn-type":[{"value":"1871-5303","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10,5]]}}}